The entities whose presence, concentration or activity are associated with a disease are known as the biomarkers for that disease. Several biomarkers for AD are currently being studied across the world. These biomarkers have different relevance at different stages of AD progression. Jack et al \cite{Jack2010,Jack_2013} describe the temporal evolution of AD biomarkers and their interrelationships amongst themselves, and with the onset and progression of clinical symptoms. The staging of the disease follow a progression from normal to mild cognitive impairment (MCI) to eventually dementia. Figure \ref{fig:hypotheticalModelJack_2013} shows the staging of the disease and the dynamics of biomarkers for AD as proposed by Jack et al in \cite{Jack2010,Jack_2013}. Well established biomarkers for AD till date are the following:
Cerbrospinal fluid (CSF) based and imaging based biomarkers targeting A\(\beta\) pathology
CSF based and imaging based biomarkers (very recent and still under research) targeting taupathy
Flurodeoxyglucose based positron emission tomography (FGD-PET) targeting neurodegeneration
Structural magnetic resonance imaging (MRI) based morphometry targeting neurodegeneration and tissue atrophy
Cognitive impairment
Cognitive impairment starts to appear many years after the changes that can be observed using other biomarkers. Following sections describe in brief the biomarkers other than cognitive impairment individually.